Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Refuge applies CAR T engineering platform to TILs through MD Anderson deal

And it’s looking for similar deals around NK cells and macrophages

By Lauren Martz, Senior Editor
May 17, 2021 12:00 PM UTC

Refuge is taking a first step in applying its synthetic biology-based cell engineering technology beyond CAR T cells through a deal with MD Anderson.

Refuge Biotechnologies Inc. will provide the University of Texas MD Anderson Cancer Center exclusive rights to its cell engineering technology for tumor infiltrating lymphocytes (TILs), another type of T cell therapy for cancer that uses the endogenous TCR rather than a CAR to target cancer cells...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Refuge Biotechnologies Inc.